PRECISION BIOSCIENCES INC

For the period ended Sep 30, 2025. Filed Nov 3, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 3, 2025

DTIL$9.68-8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Operations

(In thousands, except share and per share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue	$13	$576	$60	$68,058
Operating expenses
Research and development	13,352	13,084	39,708	43,652
General and administrative	7,328	8,767	25,008	25,722
Total operating expenses	20,680	21,851	64,716	69,374
Operating loss	(20,667)	(21,275)	(64,656)	(1,316)
Other (expense) income:
(Loss) gain from equity method investment	(591)	(875)	86	(112)
(Loss) gain on changes in other fair value adjustments	(3)	571	(2,418)	917
(Loss) gain on change in fair value of warrant liability	(1,179)	3,647	(1,230)	21,798
Interest expense	(362)	(256)	(1,074)	(1,390)
Interest income	1,027	1,763	3,466	5,269
Gain (loss) on disposal of assets	3	—	(31)	(254)
Total other (expense) income	(1,105)	4,850	(1,201)	26,228
(Loss) income from operations	$(21,772)	$(16,425)	$(65,857)	$24,912
Net (loss) income	$(21,772)	$(16,425)	$(65,857)	$24,912
Net (loss) income per share
Basic	$(1.84)	$(2.25)	$(6.14)	$3.87
Diluted	$(1.84)	$(2.25)	$(6.14)	$3.78
Weighted-average shares of common stock outstanding
Basic	11,818,145	7,287,173	10,728,199	6,441,375
Diluted	11,818,145	7,287,173	10,728,199	6,590,885

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.